Rockefeller Capital Management
ATRA icon

Rockefeller Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Rockefeller Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92 Hold
8
– – ﹤0.01% 4690
2026
Q1 		$38 Hold
8
– – ﹤0.01% 4652
2025
Q4 		$145 Hold
8
– – ﹤0.01% 4610
2025
Q3 		$115 Buy
+8
New +$92 ﹤0.01% 4371
2023
Q3 		– Sell
-2,157
Closed -$86.8K – 1505
2023
Q2 		$86.8K Hold
2,157
– – ﹤0.01% 1785
2023
Q1 		$156K Hold
2,157
– – ﹤0.01% 1856
2022
Q4 		$176K Hold
2,157
– – ﹤0.01% 1721
2022
Q3 		$203K Buy
2,157
+420
+24% +$47.2K ﹤0.01% 1645
2022
Q2 		$338K Buy
1,737
+200
+13% +$32.6K ﹤0.01% 1427
2022
Q1 		$356K Sell
1,537
-20
-1% -$6.37K ﹤0.01% 1457
2021
Q4 		$613K Buy
1,557
+37
+2% +$15.6K ﹤0.01% 1245
2021
Q3 		$680K Buy
1,520
+590
+63% +$211K ﹤0.01% 1147
2021
Q2 		$361K Sell
930
-300
-24% -$107K ﹤0.01% 1318
2021
Q1 		$441K Buy
1,230
+330
+37% +$146K ﹤0.01% 1060
2020
Q4 		$441K Hold
900
– – ﹤0.01% 952
2020
Q3 		$291K Buy
+900
New +$306K ﹤0.01% 937

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rockefeller Capital Management's ATRA Position: Q2 2026 in Review

Rockefeller Capital Management held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 8 shares worth $92. The position accounts for ﹤0.01% of the portfolio, ranked #4690.

Rockefeller Capital Management first reported a position in ATRA in Q3 2020 and has held it in 16 quarters since. The position peaked at $680K in Q3 2021. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Rockefeller Capital Management held 8 shares of Atara Biotherapeutics worth $92 as of Q2 2026.
  • Rockefeller Capital Management left its Atara Biotherapeutics share count unchanged in Q2 2026.
  • Atara Biotherapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4690 holding.
  • Rockefeller Capital Management first reported a position in Atara Biotherapeutics in Q3 2020 and has held it in 16 quarters since.
  • Rockefeller Capital Management's Atara Biotherapeutics position peaked at $680K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.